Immunotherapy for Rare Anti-IgLON5 Disease: Early Treatment Improves Outcomes

Research supporting this work received financial backing from the German federal Ministry of Education and Research, specifically through grants Connect Generates 01GM1908A and 01GM2208. Additional funding was provided by the Spanish National Fund PI/21/00165, a collaborative effort between the Instituto de Salud Carlos III (ISCIII) and the European Union via the Feder/FSE program. The Epilepsienl project, identified as project number NEF 19-08, also contributed to the study’s financial resources.

A study lead by Thomas Grüter and colleagues, detailing the impact of early intravenous immunoglobulin treatment on patients diagnosed with Anti-IgLON5 disease, has been published in the journal JAMA Neurology. The research, slated for release in 2025, is accessible online with DOI: 10.1001/jamaneurol.2025.2574.